Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study

Edwin A. Basak,Niels S. Vermeer,Karlijn de Joode,Daan P. Hurkmans,Dorian E.M. Velthuis,Esther Oomen-de Hoop,Marco W.J. Schreurs,Sander Bins,Stijn L.W. Koolen,Reno Debets,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Arjen Joosse,Ron H.J. Mathijssen

European Journal of Cancer（2022）

引用 5|浏览9

暂无评分

摘要

•12% of patients receiving anti-PD-1 monotherapy experienced grade ≥3 toxicities.•44% of patients receiving anti-PD-1 + CTLA-4 therapy experienced grade ≥3 toxicities.•No clinical factor was associated with toxicities during anti-PD-1 (+CTLA4) therapy.•This was found across tumour types, as well as in melanoma and NSCLC patients.

查看译文

关键词

Anti-PD-1,Anti-CTLA-4,Severe immune-related adverse events,Melanoma,NSCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要